Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGN phase 3 study of atrasentan in IgA nephropathy at risk of progressive kidney function loss
CTR20212405Phase 3Active
- Sponsor
- Novartis
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atrasentan in IgA nephropathy (IgAN), sponsored by Novartis. Started Jun 2022; status: active.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20212405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212405.